MaaT Pharma Randomizes First Patient in Phase 2 IMMUNOLIFE Trial Evaluating MaaT033 to Overcome Immunotherapy Resistance in NSCLC

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecos...

January 22, 2026 | Thursday | News
Ant Group Upgrades AQ Health Assistant With DeepSearch to Support Evidence-Based Clinical Decision-Making

Ant Group  announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capabili...

January 22, 2026 | Thursday | News
Parse Biosciences and Graph Therapeutics Partner to Build a Large-Scale Immune Cell Perturbation Atlas

Parse Biosciences and Graph Therapeutics (Graph) announced a strategic partnership to create one of the largest and most comprehensive immune cell pertur...

January 22, 2026 | Thursday | News
LEO Pharma Initiates Phase 3 DELTA CARE 1 Trial of Delgocitinib Cream in Lichen Sclerosus

The phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitini...

January 22, 2026 | Thursday | News
Bayer and Vanderbilt University Medical Center Form Five-Year Strategic Collaboration to Advance Innovative Therapies

-Bayer and Vanderbilt University Medical Center (VUMC) announced that they have entered a strategic five-year collaboration agreement to advance innovati...

January 21, 2026 | Wednesday | News
ImmunityBio Holds FDA End-of-Phase Meeting on sBLA for ANKTIVA® Plus BCG in Papillary NMIBC

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA...

January 21, 2026 | Wednesday | News
Valneva Voluntarily Withdraws U.S. BLA and IND for Chikungunya Vaccine IXCHIQ® Following FDA Clinical Hold

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced that the Company has decided to voluntarily withdraw the biologics...

January 21, 2026 | Wednesday | News
ImmunityBio’s CAR-NK Program Delivers Durable Responses Without Chemotherapy in Rare B-Cell Lymphoma

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced updated efficacy and safety results from the ongoing QUILT-106 clin...

January 20, 2026 | Tuesday | News
Epcoritamab Demonstrates Statistically Significant PFS Improvement in Phase 3 DLBCL Study

Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps Ge...

January 20, 2026 | Tuesday | News
Organon Secures FDA Approval to Extend NEXPLANON Use to Five Years

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced that th...

January 20, 2026 | Tuesday | News
Ouroboros Family Founders Fund to Lead $60 Million Series A Financing in Cytotheryx

Ouroboros Family Founders Fund I, LP announced this week it will lead a $60 million Series A financing in Cytotheryx, Inc., a preclinical cell therapy comp...

January 19, 2026 | Monday | News
AbbVie and Genmab Report Positive PFS Results from Phase 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Relapsed/Refractory DLBCL

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss ...

January 19, 2026 | Monday | News
China Approves Sanofi’s Myqorzo and Redemplo for Cardiovascular and Rare Metabolic Diseases

Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-ter...

January 16, 2026 | Friday | News
ElpasBio Partners With Fosun Kairos to Commercialize AlloJoin® Stem Cell Therapy for Knee Osteoarthritis in Greater China

ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, announced that it has entered into a col...

January 15, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close